Advisory · Rare Disease
Smaller patient populations, clearer endpoints, premium economics.
Ambrosia provides senior-led advisory for rare disease licensing, M&A, and strategic partnerships — backed by a proprietary database of 250 verified rare disease transactions.
Deal Landscape
What rare disease transactions actually look like.
Verified Transactions
250
Median Upfront
$110M
Key Structure Insight
Rare disease commands 28.7% upfront ratios — highest of any TA
Selected Work
Rare Disease·Rare disease program — global licensing engagement with milestone structure optimization
Related Insights
Research relevant to rare disease.
Discuss your rare disease transaction.
We’ll meet you at peer level — anywhere in the world.